- Home
- TRVI vs MEGI Comparison
TRVI vs MEGI Comparison
Compare TRVI & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- MEGI
- Stock Information
- Founded
- TRVI 2011
- MEGI 2021
- Country
- TRVI United States
- MEGI United States
- Employees
- TRVI N/A
- MEGI N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- TRVI Health Care
- MEGI Finance
- Exchange
- TRVI Nasdaq
- MEGI Nasdaq
- Market Cap
- TRVI 725.7M
- MEGI 729.7M
- IPO Year
- TRVI 2019
- MEGI N/A
- Fundamental
- Price
- TRVI $6.89
- MEGI $14.35
- Analyst Decision
- TRVI Strong Buy
- MEGI
- Analyst Count
- TRVI 9
- MEGI 0
- Target Price
- TRVI $19.94
- MEGI N/A
- AVG Volume (30 Days)
- TRVI 1.6M
- MEGI 178.0K
- Earning Date
- TRVI 08-07-2025
- MEGI 01-01-0001
- Dividend Yield
- TRVI N/A
- MEGI 11.40%
- EPS Growth
- TRVI N/A
- MEGI N/A
- EPS
- TRVI N/A
- MEGI N/A
- Revenue
- TRVI N/A
- MEGI N/A
- Revenue This Year
- TRVI N/A
- MEGI N/A
- Revenue Next Year
- TRVI N/A
- MEGI N/A
- P/E Ratio
- TRVI N/A
- MEGI N/A
- Revenue Growth
- TRVI N/A
- MEGI N/A
- 52 Week Low
- TRVI $2.36
- MEGI $10.63
- 52 Week High
- TRVI $7.48
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- TRVI 64.54
- MEGI 58.45
- Support Level
- TRVI $5.41
- MEGI $14.06
- Resistance Level
- TRVI $6.08
- MEGI $14.41
- Average True Range (ATR)
- TRVI 0.32
- MEGI 0.19
- MACD
- TRVI 0.14
- MEGI -0.00
- Stochastic Oscillator
- TRVI 89.91
- MEGI 74.53
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.